

DATE: 11.08.23

TO: METROPLUSHEALTH PROVIDERS

RE: APPROVAL OF THE NOVAVAX COVID 19 VACCINE

IMPACTS – METROPLUSHEALTH PRODUCTS

SUMMARY

Effective October 3, 2023, the Federal Drug Administration (FDA) announced the approval of the updated 2023–2024 monovalent XBB.1.5 variant Novavax COVID-19 Vaccine, Adjuvanted.

Reimbursement to NYS Medicaid enrolled and qualified Providers:

- Per State guidelines, MPH will not reimburse for the cost of any COVID-19 vaccines because it is available at no cost to providers.
- MPH will reimburse for the administration of COVID-19 vaccines that have been issued an EUA by the FDA for the prevention of COVID-19.
- The updated Novavax COVID-19 vaccine adds a third option for use in individuals **12 years of age and older**.
- Members will be covered with no cost sharing.

Dosage limits per FDA guidance are as follows:

- **Individuals previously vaccinated with any COVID-19 vaccine:**
 - one dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is administered at least 2 months after receipt of the last previous dose of an original monovalent (Original) or bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine.
- **Individuals not previously vaccinated with any COVID-19 vaccine:**
 - two doses of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) are administered three weeks apart.

- **Immunocompromised individuals:**
 - an additional dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) may be administered at least 2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula).

Please refer to CMS and NYSDOH billing and reimbursement guidelines.